Compare Avient Corporation (AVNT) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Boston Scientific Corporation — how do they compare? Avient Corporation trades at $44.87 (market cap $4.17B), while Boston Scientific Corporation trades at $51.21 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 17.8× Avient Corporation's market cap, and Avient Corporation pays a 2.42% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| AVNT | BSX | |
|---|---|---|
Market Cap | $4.17B | $74.19B |
Sector | Technology | Health |
52-Week High | $45.69 | $108.14 |
52-Week Low | $27.48 | $42.63 |
Enterprise Value | $5.62B | $86.27B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient (AVNT) trades at $44.80, down 1.86% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.96 beating expectations by $0.07, marking the third consecutive earnings beat. Revenue growth of 5.8% to $917 million in Q2 2026 and improved net income margin of 5.1% reflect operational strength. Analyst consensus remains positive with 60% buy ratings and a $49.00 price target representing 9.4% upside potential.
Avient presents a favorable investment case with consistent earnings outperformance and positive analyst sentiment. The stock offers dividend income with recent $0.28 quarterly payments. Key risks include potential margin pressure from input costs and market volatility. Technical indicators show near-term overbought conditions with RSI at 78.87, suggesting possible consolidation before further upside toward the $49 consensus target.
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
